Validation of the Atopic Dermatitis Control Tool (ADCT) and a Comparison with the Recap of Atopic Eczema Questionnaire (RECAP)
DOI:
https://doi.org/10.2340/actadv.v105.42364Keywords:
atopic dermatitis, validation study, Atopic Dermatitis Control Tool, measurement propertiesAbstract
The Atopic Dermatitis Control Tool (ADCT) has not been validated in the Dutch population, and comparisons with the Recap of atopic eczema (RECAP) questionnaire are still lacking. This prospective study was conducted at a Dutch tertiary hospital between June 2021 and December 2022, to assess measurement properties of the Dutch ADCT in adults with atopic dermatitis (AD) and compare it with RECAP. Participants completed the ADCT, RECAP, and reference instruments including Patient’s Global Assessment (PtGA), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), quality-of-life questionnaire of the EuroQol Group (EQ-5D-5L), Numeric Rating Scale (NRS) peak itch/sleep disturbance, Skindex-29, and Global Rating of Change (GRC), at baseline, 1–3 days, and 4–12 weeks. Construct validity was assessed through a priori hypotheses, whilst reliability was evaluated with standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement). Interpretability was examined using anchor-based approaches. In total, 196 adults with AD were included. Among a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. The SEMagreement was 1.15, and the ICCagreement was 0.983. The final bandings for the ADCT were established, with a binary cutoff of ≥ 6 indicating uncontrolled AD. The smallest detectable change (SDC) was 3.2, and the minimally important change (MIC) value from predictive modelling was 2.9. Furthermore, the ADCT exhibited high correlations with RECAP at all levels (most correlations being above 0.80). These results demonstrated the Dutch ADCT as a valid, reliable, and responsive tool, and have important clinical implications.
Downloads
References
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol 2021; 185: 139-146.
https://doi.org/10.1111/bjd.19751 DOI: https://doi.org/10.1111/bjd.19751
Leshem YA, Chalmers JR, Apfelbacher C, Katoh N, Gerbens LAA, Schmitt J, et al. Meas-uring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. JAMA Dermatol 2022; 158: 1429-1435.
https://doi.org/10.1001/jamadermatol.2022.4211 DOI: https://doi.org/10.1001/jamadermatol.2022.4211
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
https://doi.org/10.1080/03007995.2019.1699516 DOI: https://doi.org/10.1080/03007995.2019.1699516
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15.
https://doi.org/10.1186/s12895-019-0095-3 DOI: https://doi.org/10.1186/s12895-019-0095-3
Luan TT, Peng CY, Song XT, Liao SL, Zhao ZT. [Validation study of the Chinese version of atopic dermatitis control tool]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57: 422-426.
Kido-Nakahara M, Yokote G, Yoshida M, Furue M, Nakahara T. Atopic Dermatitis Control Tool (ADCT): A useful tool for self-evaluation in patients with atopic dermatitis. J Dermatol 2021; 48: 1951-1952.
https://doi.org/10.1111/1346-8138.16176 DOI: https://doi.org/10.1111/1346-8138.16176
Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol 2020; 183: 524-536.
https://doi.org/10.1111/bjd.18780 DOI: https://doi.org/10.1111/bjd.18780
Zhang J, Ragamin A, Romeijn GLE, Loman L, Oosterhaven JAF, Schuttelaar MLA. Validi-ty, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire. Br J Dermatol 2023; 189: 578-587.
https://doi.org/10.1093/bjd/ljad247 DOI: https://doi.org/10.1093/bjd/ljad247
Ragamin A, Zhang J, Pasmans SGMA, Schappin R, Romeijn GLE, van Reusel MA, et al. The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children. Br J Dermatol 2024; 190: 867-875.
https://doi.org/10.1093/bjd/ljae017 DOI: https://doi.org/10.1093/bjd/ljae017
Onteniente-Gomis MM, Ortiz-Romero PL, Tous Romero F, Salamanca Castro AB, Ortiz de Frutos FJ. Spanish Version of the RECAP Questionnaire to Assess Control of Atopic Ec-zema: Translation, Cultural Adaptation, Validation, and Correlations with Other Patient-Reported Outcome Measures. Actas Dermosifiliogr 2023; 114: 488-493. DOI: https://doi.org/10.1016/j.ad.2023.05.009
https://doi.org/10.1016/j.ad.2023.02.018 DOI: https://doi.org/10.1016/j.ad.2023.02.018
Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC, et al. COSMIN Study Design checklist for Patient-reported outcome measurement instruments. 2019.
de Vet HC, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine: a practical guide. Cam- bridge University Press; 2011.
https://doi.org/10.1017/CBO9780511996214 DOI: https://doi.org/10.1017/CBO9780511996214
Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-416.
https://doi.org/10.1111/j.1365-2133.1994.tb08532.x DOI: https://doi.org/10.1111/j.1365-2133.1994.tb08532.x
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
https://doi.org/10.1034/j.1600-0625.2001.100102.x DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x
Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.
https://doi.org/10.1111/bjd.15641 DOI: https://doi.org/10.1111/bjd.15641
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The de-velopment and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol 2020; 83: 839-846.
https://doi.org/10.1016/j.jaad.2020.04.104 DOI: https://doi.org/10.1016/j.jaad.2020.04.104
Prinsen C a. C, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COS-MIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 2018; 27: 1147-1157.
https://doi.org/10.1007/s11136-018-1798-3 DOI: https://doi.org/10.1007/s11136-018-1798-3
Anthoine E, Moret L, Regnault A, Sébille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes 2014; 12: 176.
https://doi.org/10.1186/s12955-014-0176-2 DOI: https://doi.org/10.1186/s12955-014-0176-2
de Vet HCW, Terwee CB, Knol DL, Bouter LM. When to use agreement versus reliability measures. J Clin Epidemiol 2006; 59: 1033-1039.
https://doi.org/10.1016/j.jclinepi.2005.10.015 DOI: https://doi.org/10.1016/j.jclinepi.2005.10.015
Terluin B, Eekhout I, Terwee CB, de Vet HCW. Minimal important change (MIC) based on a predictive modeling approach was more precise than MIC based on ROC analysis. J Clin Epidemiol 2015; 68: 1388-1396.
https://doi.org/10.1016/j.jclinepi.2015.03.015 DOI: https://doi.org/10.1016/j.jclinepi.2015.03.015
Terluin B, Eekhout I, Terwee CB. The anchor-based minimal important change, based on re-ceiver operating characteristic analysis or predictive modeling, may need to be adjusted for the proportion of improved patients. J Clin Epidemiol 2017; 83: 90-100.
https://doi.org/10.1016/j.jclinepi.2016.12.015 DOI: https://doi.org/10.1016/j.jclinepi.2016.12.015
McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995; 4: 293-307.
https://doi.org/10.1007/BF01593882 DOI: https://doi.org/10.1007/BF01593882
Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining respon-siveness and minimally important differences for patient-reported outcomes. J Clin Epi-demiol 2008; 61: 102-109.
https://doi.org/10.1016/j.jclinepi.2007.03.012 DOI: https://doi.org/10.1016/j.jclinepi.2007.03.012
Oosterhaven JAF, Spekhorst LS, Zhang J, Voorberg AN, Romeijn GLE, Boesjes CM, et al. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry. J Dermatol Treat 2022; 33: 1986-1989.
https://doi.org/10.1080/09546634.2021.1937485 DOI: https://doi.org/10.1080/09546634.2021.1937485
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
https://doi.org/10.1111/bjd.12590 DOI: https://doi.org/10.1111/bjd.12590
Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, White T, et al. Validation of patient-reported global severity of atopic dermatitis in adults. Allergy 2018; 73: 451-458.
https://doi.org/10.1111/all.13309 DOI: https://doi.org/10.1111/all.13309
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713.
https://doi.org/10.1111/1523-1747.ep12365600 DOI: https://doi.org/10.1111/1523-1747.ep12365600
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-343.
https://doi.org/10.3109/07853890109002087 DOI: https://doi.org/10.3109/07853890109002087
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak Pruritus Nu-merical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.
https://doi.org/10.1111/bjd.17744 DOI: https://doi.org/10.1111/bjd.17744
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Junfen Zhang, Leon Miltner , Laura Loman , Aviël Ragamin , Jart A.F. Oosterhaven , Marie L.A. Schuttelaar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
